229 related articles for article (PubMed ID: 33352201)
1. Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial.
Yhim HY; Kim T; Kim SJ; Shin HJ; Koh Y; Kim JS; Park J; Park GS; Kim WS; Moon JH; Yang DH
Ann Oncol; 2021 Apr; 32(4):552-559. PubMed ID: 33352201
[TBL] [Abstract][Full Text] [Related]
2. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.
Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS
Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158
[TBL] [Abstract][Full Text] [Related]
3. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer.
Kim RD; Alberts SR; Peña C; Genvresse I; Ajavon-Hartmann A; Xia C; Kelly A; Grilley-Olson JE
Br J Cancer; 2018 Feb; 118(4):462-470. PubMed ID: 29348486
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified.
Qi F; Dong M; He X; Li Y; Wang W; Liu P; Yang J; Gui L; Zhang C; Yang S; Zhou S; Shi Y
Ann Hematol; 2017 Feb; 96(2):245-251. PubMed ID: 27858107
[TBL] [Abstract][Full Text] [Related]
6. A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.
Pellegrini C; Dodero A; Chiappella A; Monaco F; Degl'Innocenti D; Salvi F; Vitolo U; Argnani L; Corradini P; Zinzani PL;
J Hematol Oncol; 2016 Apr; 9():38. PubMed ID: 27071522
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
Dreyling M; Morschhauser F; Bouabdallah K; Bron D; Cunningham D; Assouline SE; Verhoef G; Linton K; Thieblemont C; Vitolo U; Hiemeyer F; Giurescu M; Garcia-Vargas J; Gorbatchevsky I; Liu L; Koechert K; Peña C; Neves M; Childs BH; Zinzani PL
Ann Oncol; 2017 Sep; 28(9):2169-2178. PubMed ID: 28633365
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma: A meta-analysis of prospective clinical trials.
Wang J; Zhou H; Mu M; Zhao A; Cai Z; Li L; Wang M; Niu T
Front Immunol; 2022; 13():1034253. PubMed ID: 36439091
[TBL] [Abstract][Full Text] [Related]
9. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
Matasar MJ; Capra M; Özcan M; Lv F; Li W; Yañez E; Sapunarova K; Lin T; Jin J; Jurczak W; Hamed A; Wang MC; Baker R; Bondarenko I; Zhang Q; Feng J; Geissler K; Lazaroiu M; Saydam G; Szomor Á; Bouabdallah K; Galiulin R; Uchida T; Soler LM; Cao A; Hiemeyer F; Mehra A; Childs BH; Shi Y; Zinzani PL
Lancet Oncol; 2021 May; 22(5):678-689. PubMed ID: 33848462
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
Dreyling M; Santoro A; Mollica L; Leppä S; Follows G; Lenz G; Kim WS; Nagler A; Dimou M; Demeter J; Özcan M; Kosinova M; Bouabdallah K; Morschhauser F; Stevens DA; Trevarthen D; Munoz J; Rodrigues L; Hiemeyer F; Miriyala A; Garcia-Vargas J; Childs BH; Zinzani PL
Am J Hematol; 2020 Apr; 95(4):362-371. PubMed ID: 31868245
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial.
Grunenberg A; Kaiser LM; Woelfle S; Schmelzle B; Viardot A; Möller P; Barth TFE; Muche R; Dreyhaupt J; Raderer M; Kiesewetter B; Buske C
BMC Cancer; 2021 Jun; 21(1):749. PubMed ID: 34187401
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.
Evens AM; Rosen ST; Helenowski I; Kline J; Larsen A; Colvin J; Winter JN; van Besien KM; Gordon LI; Smith SM
Br J Haematol; 2013 Oct; 163(1):55-61. PubMed ID: 23927371
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
Dreyling M; Santoro A; Mollica L; Leppä S; Follows GA; Lenz G; Kim WS; Nagler A; Panayiotidis P; Demeter J; Özcan M; Kosinova M; Bouabdallah K; Morschhauser F; Stevens DA; Trevarthen D; Giurescu M; Cupit L; Liu L; Köchert K; Seidel H; Peña C; Yin S; Hiemeyer F; Garcia-Vargas J; Childs BH; Zinzani PL
J Clin Oncol; 2017 Dec; 35(35):3898-3905. PubMed ID: 28976790
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350.
Mahadevan D; Unger JM; Spier CM; Persky DO; Young F; LeBlanc M; Fisher RI; Miller TP
Cancer; 2013 Jan; 119(2):371-9. PubMed ID: 22833464
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma.
Panayiotidis P; Follows GA; Mollica L; Nagler A; Özcan M; Santoro A; Stevens D; Trevarthen D; Hiemeyer F; Garcia-Vargas J; Childs BH; Zinzani PL; Dreyling M
Blood Adv; 2021 Feb; 5(3):823-828. PubMed ID: 33560394
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
[TBL] [Abstract][Full Text] [Related]
17. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
Damaj G; Gressin R; Bouabdallah K; Cartron G; Choufi B; Gyan E; Banos A; Jaccard A; Park S; Tournilhac O; Schiano-de Collela JM; Voillat L; Joly B; Le Gouill S; Saad A; Cony-Makhoul P; Vilque JP; Sanhes L; Schmidt-Tanguy A; Bubenheim M; Houot R; Diouf M; Marolleau JP; Béné MC; Martin A; Lamy T
J Clin Oncol; 2013 Jan; 31(1):104-10. PubMed ID: 23109692
[TBL] [Abstract][Full Text] [Related]
18. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P
Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412
[TBL] [Abstract][Full Text] [Related]
19. Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma.
Eltantawy A; Vallejos X; Sebea E; Evans K
Ann Pharmacother; 2019 Sep; 53(9):954-958. PubMed ID: 30813760
[No Abstract] [Full Text] [Related]
20. [Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma].
Yao Z; Yang S; Zhao Y; Yao S; Guo H; Liu Y
Zhonghua Zhong Liu Za Zhi; 2014 Jul; 36(7):541-5. PubMed ID: 25327662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
